Next Article in Journal
The Trend of Changes in Adiponectin, Resistin, and Adiponectin–Resistin Index Values in Type 2 Diabetic Patients with the Development of Metabolic Syndrome
Next Article in Special Issue
Impact of DPP-4 Inhibitors in Patients with Diabetes Mellitus and Heart Failure: An In-Depth Review
Previous Article in Journal
Advances in Imaging-Based Machine Learning and Therapeutic Technology in the Management of Retinal Diseases
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

Transforming Diabetes Care: The Expanding Role of DPP-4 Inhibitors in Cardiovascular and Renal Protection

Medicine Department, Institut d’Investigació i Innovació Parc Taulí I3PT, Parc Taulí Hospital Universitari, 08208 Sabadell, Spain
Medicina 2024, 60(11), 1793; https://doi.org/10.3390/medicina60111793
Submission received: 9 October 2024 / Revised: 27 October 2024 / Accepted: 31 October 2024 / Published: 1 November 2024

1. Introduction

The approach to managing type 2 diabetes mellitus (T2DM) has significantly progressed, evolving beyond strict glycemic control to addressing the wider complications associated with the disease, including cardiovascular disease (CVD) and chronic kidney disease (CKD) [1,2]. These conditions are prevalent in diabetic patients, contributing to high rates of morbidity and mortality. Dipeptidyl peptidase-4 (DPP-4) inhibitors, known primarily for their glucose-lowering effects, have become integral in the therapeutic regimen for T2DM due to their low risk of hypoglycemia and weight neutrality, making them particularly suitable for a diverse patient population [3,4]. In recent years, research has uncovered potential cardiovascular and renal protective effects, broadening the scope of their therapeutic application [5,6,7]. Given the critical need to improve outcomes for high-risk populations, this Special Issue encourages the submission of original research, reviews, and clinical studies focused on the expanding therapeutic potential of DPP-4 inhibitors.

2. DPP-4 Inhibitors: Shifting Beyond Glycemic Control

DPP-4 inhibitors control glucose effectively by preventing the breakdown of incretin hormones, thus enhancing insulin secretion and inhibiting glucagon release [8,9]. Unlike older antidiabetic medications, DPP-4 inhibitors achieve this without causing weight gain or significant hypoglycemia, making them particularly beneficial for patients with cardiovascular and renal comorbidities [10]. Recent research highlights that DPP-4 inhibitors’ impact extends beyond glycemic control, with studies indicating potential benefits for cardiovascular and renal health, particularly in patients with heart failure and CKD [11,12]. This multifaceted therapeutic role positions DPP-4 inhibitors as valuable agents in managing T2DM and its associated complications. We invite researchers to explore this area further to uncover the non-glycemic advantages that may enhance patient outcomes.

3. DPP-4 Inhibitors and Heart Failure: A Critical Examination

Patients with diabetes are at an increased risk of developing heart failure (HF), a condition that complicates diabetes management and worsens prognosis [13]. The cardiovascular safety of antidiabetic drugs is thus an area of considerable interest, especially following the SAVOR-TIMI 53 trial, which reported an unexpected increase in HF hospitalizations among patients treated with saxagliptin [14]. However, subsequent trials, including EXAMINE, which examined alogliptin, and TECOS, which studied sitagliptin, did not observe a similar increase in HF risk, suggesting that the cardiovascular effects of DPP-4 inhibitors may vary by agent and patient profile [15,16,17,18]. These diverse findings underscore the need for additional research to clarify the cardiovascular effects of DPP-4 inhibitors and identify patient subsets that may benefit or experience increased risk. Exploring these complex relationships further will help inform the safe integration of DPP-4 inhibitors in HF management for diabetic patients, providing clinicians with greater insights into patient-tailored therapeutic strategies.

4. Renal Protection: A Promising, Yet Incomplete, Picture

CKD remains a challenging and often devastating complication of diabetes, with limited treatment options as the disease progresses [19]. Certain DPP-4 inhibitors, such as linagliptin, can be administered in patients with advanced CKD without dose adjustments, making them a favorable choice for diabetic patients with renal impairment [20]. While DPP-4 inhibitors have demonstrated efficacy in slowing the progression of albuminuria, their impact on renal outcomes remains modest, particularly when compared to the more potent renoprotective effects of sodium-glucose co-transporter 2 (SGLT-2) inhibitors [21,22]. Nonetheless, the anti-inflammatory and anti-fibrotic properties of DPP-4 inhibitors suggest potential long-term benefits, a hypothesis that warrants further investigation [23]. The CARMELINA trial, which evaluated linagliptin, confirmed its renal safety but highlighted the need for additional studies to assess its potential for direct renal protection [24]. We encourage research submissions on DPP-4 inhibitors in combination with other renal protective agents, such as SGLT-2 inhibitors or GLP-1 receptor agonists, to further optimize CKD management in diabetic patients.

5. DPP-4 Inhibitors in Cardiovascular-Renal Strategy: A Multifactorial Approach

As diabetes management continues to evolve, DPP-4 inhibitors should be considered within a broader cardiovascular and renal strategy [25]. For diabetic patients at low cardiovascular or renal risk, DPP-4 inhibitors remain an excellent choice for glycemic control due to their favorable safety profile, convenience, and efficacy across diverse patient populations, including the elderly [26,27]. In higher-risk patients with established heart failure or advanced CKD, treatment decisions become more nuanced, and DPP-4 inhibitors may be best used in combination with other agents, such as SGLT-2 inhibitors, which provide greater cardiovascular and renal benefits [28,29]. The future of diabetes management likely lies in such combination therapies, with DPP-4 inhibitors being integrated into multi-drug regimens to achieve optimal outcomes for patients facing complex clinical challenges. Studies investigating these combined therapeutic strategies and their impact on cardiovascular and renal health will be of particular interest.

6. A Call for Research and Contributions

This Special Issue seeks to expand the current knowledge on DPP-4 inhibitors in diabetes care. Researchers are invited to submit articles that delve into the cardiovascular and renal effects of DPP-4 inhibitors, emphasizing studies that provide mechanistic insights, real-world applications, and innovative combination therapies. Through these contributions, we aim to advance our understanding of DPP-4 inhibitors and improve patient care by addressing the dual challenges of cardiovascular and renal disease in diabetes management.

Funding

The author did not finance this article.

Conflicts of Interest

The author declares no conflict of interest.

References

  1. Drake, T.; Landsteiner, A.; Langsetmo, L.; MacDonald, R.; Anthony, M.; Kalinowski, C.; Ullman, K.; Billington, C.J.; Kaka, A.; Sultan, S.; et al. Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians. Ann. Intern. Med. 2024, 177, 618–632. [Google Scholar] [CrossRef] [PubMed]
  2. Fu, W.J.; Huo, J.L.; Mao, Z.H.; Pan, S.K.; Liu, D.W.; Liu, Z.S.; Wu, P.; Gao, Z.X. Emerging role of antidiabetic drugs in cardiorenal protection. Front. Pharmacol. 2024, 15, 1349069. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  3. Liu, H.; Guo, L.; Xing, J.; Li, P.; Sang, H.; Hu, X.; Du, Y.; Zhao, L.; Song, R.; Gu, H. The protective role of DPP4 inhibitors in atherosclerosis. Eur. J. Pharmacol. 2020, 875, 173037. [Google Scholar] [CrossRef] [PubMed]
  4. Komamine, M.; Kajiyama, K.; Ishiguro, C.; Uyama, Y. Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study. Pharmacoepidemiol. Drug Saf. 2019, 28, 1166–1174. [Google Scholar] [CrossRef] [PubMed]
  5. Enzan, N.; Matsushima, S.; Kaku, H.; Tohyama, T.; Nagata, T.; Ide, T.; Tsutsui, H. Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure with Preserved Ejection Fraction and Diabetes. JACC Asia 2023, 3, 93–104. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  6. Bae, J.H.; Kim, S.; Park, E.G.; Kim, S.G.; Hahn, S.; Kim, N.H. Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Endocrinol. Metab. 2019, 34, 80–92. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  7. Ferreira, J.P.; Mehta, C.; Sharma, A.; Nissen, S.E.; Rossignol, P.; Zannad, F. Alogliptin after acute coronary syndrome in patients with type 2 diabetes: A renal function stratified analysis of the EXAMINE trial. BMC Med. 2020, 18, 165. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  8. Ussher, J.R.; Greenwell, A.A.; Nguyen, M.A.; Mulvihill, E.E. Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms with Cardiovascular Outcome Trials. Diabetes 2022, 71, 173–183. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  9. Al Tuhaifi, T.; Zhong, J.; Yang, H.C.; Fogo, A.B. Effects of Dipeptidyl Peptidase-4 Inhibitor and Angiotensin-Converting Enzyme Inhibitor on Experimental Diabetic Kidney Disease. Lab. Invest. 2024, 104, 100305. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  10. Chai, S.; Niu, Y.; Liu, F.; Wu, S.; Yang, Z.; Sun, F. Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined with Oral Hypoglycemic Drugs: Umbrella Review. J. Diabetes Res. 2024, 2024, 8145388. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  11. Singh, A.K.; Singh, R. Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors. World J. Diabetes. 2022, 13, 466–470. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  12. Chikata, Y.; Iwata, H.; Minamino, T. The Prognostic Efficacy of DPP-4 Inhibitors in Asian HFpEF: Do They Still Have a Chance? JACC Asia 2023, 3, 105–107. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  13. Taylor, S.I.; Yazdi, Z.S.; Beitelshees, A.L. Pharmacological treatment of hyperglycemia in type 2 diabetes. J. Clin. Invest. 2021, 131, e142243. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  14. White, W.B.; Heller, S.R.; Cannon, C.P.; Howitt, H.; Khunti, K.; Bergenstal, R.M. EXAMINE Investigators. Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial. Am. J. Med. 2018, 131, 813–819.e5. [Google Scholar] [CrossRef] [PubMed]
  15. Scirica, B.M.; Im, K.; Murphy, S.A.; Kuder, J.F.; Rodriguez, D.A.; Lopes, R.D.; Green, J.B.; Ruff, C.T.; Sabatine, M.S. Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors. Clin. Cardiol. 2022, 45, 794–801. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  16. Yu, J.; Liu, Y.; Li, H.; Zhang, P. Pathophysiology of diabetic kidney disease and autophagy: A review. Medicine 2023, 102, e33965. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  17. Gupta, S.; Dominguez, M.; Golestaneh, L. Diabetic Kidney Disease: An Update. Med. Clin. North. Am. 2023, 107, 689–705. [Google Scholar] [CrossRef] [PubMed]
  18. Tuttle, K.R.; Agarwal, R.; Alpers, C.E.; Bakris, G.L.; Brosius, F.C.; Kolkhof, P.; Uribarri, J. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022, 102, 248–260. [Google Scholar] [CrossRef] [PubMed]
  19. Rayego-Mateos, S.; Rodrigues-Diez, R.R.; Fernandez-Fernandez, B.; Mora-Fernández, C.; Marchant, V.; Donate-Correa, J.; Navarro-González, J.F.; Ortiz, A.; Ruiz-Ortega, M. Targeting inflammation to treat diabetic kidney disease: The road to 2030. Kidney Int. 2023, 103, 282–296. [Google Scholar] [CrossRef] [PubMed]
  20. Anders, H.J.; Huber, T.B.; Isermann, B.; Schiffer, M. CKD in diabetes: Diabetic kidney disease versus nondiabetic kidney disease. Nat. Rev. Nephrol. 2018, 14, 361–377. [Google Scholar] [CrossRef] [PubMed]
  21. DeFronzo, R.A.; Reeves, W.B.; Awad, A.S. Pathophysiology of diabetic kidney disease: Impact of SGLT2 inhibitors. Nat. Rev. Nephrol. 2021, 17, 319–334. [Google Scholar] [CrossRef] [PubMed]
  22. Toyama, T.; Neuen, B.L.; Jun, M.; Ohkuma, T.; Neal, B.; Jardine, M.J.; Heerspink, H.L.; Wong, M.G.; Ninomiya, T.; Wada, T.; et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Diabetes Obes. Metab. 2019, 21, 1237–1250. [Google Scholar] [CrossRef] [PubMed]
  23. Kawanami, D.; Takashi, Y.; Takahashi, H.; Motonaga, R.; Tanabe, M. Renoprotective Effects of DPP-4 Inhibitors. Antioxidants 2021, 10, 246. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  24. Rosenstock, J.; Perkovic, V.; Johansen, O.E.; Cooper, M.E.; Kahn, S.E.; Marx, N.; Alexander, J.H.; Pencina, M.; Toto, R.D.; Wanner, C.; et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults with Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA 2019, 321, 69–79. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  25. Kutz, A.; Kim, D.H.; Wexler, D.J.; Liu, J.; Schneeweiss, S.; Glynn, R.J.; Patorno, E. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care 2023, 46, 2004–2014. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  26. Scheen, A.J. Careful use to minimize adverse events of oral antidiabetic medications in the elderly. Expert Opin. Pharmacother. 2021, 22, 2149–2165. [Google Scholar] [CrossRef] [PubMed]
  27. Nauck, M.A.; McGuire, D.K.; Pieper, K.S.; Lokhnygina, Y.; Strandberg, T.E.; Riefflin, A.; Delibasi, T.; Peterson, E.D.; White, H.D.; Scott, R.; et al. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: Observations from TECOS. Cardiovasc. Diabetol. 2019, 18, 116. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  28. Subrahmanyan, N.A.; Koshy, R.M.; Jacob, K.; Pappachan, J.M. Efficacy and Cardiovascular Safety of DPP-4 Inhibitors. Curr. Drug Saf. 2021, 16, 154–164. [Google Scholar] [CrossRef] [PubMed]
  29. Ling, J.; Ge, L.; Zhang, D.H.; Wang, Y.F.; Xie, Z.L.; Tian, J.H.; Xiao, X.H.; Yang, K.H. DPP-4 inhibitors for the treatment of type 2 diabetes: A methodology overview of systematic reviews. Acta Diabetol. 2019, 56, 7–27. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Epelde, F. Transforming Diabetes Care: The Expanding Role of DPP-4 Inhibitors in Cardiovascular and Renal Protection. Medicina 2024, 60, 1793. https://doi.org/10.3390/medicina60111793

AMA Style

Epelde F. Transforming Diabetes Care: The Expanding Role of DPP-4 Inhibitors in Cardiovascular and Renal Protection. Medicina. 2024; 60(11):1793. https://doi.org/10.3390/medicina60111793

Chicago/Turabian Style

Epelde, Francisco. 2024. "Transforming Diabetes Care: The Expanding Role of DPP-4 Inhibitors in Cardiovascular and Renal Protection" Medicina 60, no. 11: 1793. https://doi.org/10.3390/medicina60111793

APA Style

Epelde, F. (2024). Transforming Diabetes Care: The Expanding Role of DPP-4 Inhibitors in Cardiovascular and Renal Protection. Medicina, 60(11), 1793. https://doi.org/10.3390/medicina60111793

Article Metrics

Back to TopTop